Meiragtx Holdings
Meiragtx Holdings (MGTX) is a biotechnology company focused on developing innovative gene therapies for neurological and rare diseases. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary adeno-associated virus (AAV) platform to create therapies that address unmet medical needs. MGTX's core products include advanced gene therapies designed to treat conditions such as neurodegenerative disorders, providing hope for patients suffering from debilitating diseases.